What Cazitel Plus XL Treats: Main Uses and Benefits

Cazitel Plus XL is a veterinary medicinal product used in situations involving certain distressing symptoms caused by common intestinal parasites in dogs. It is applied across therapeutic domains where short-term symptom management is appropriate, and is relevant for easing discomfort or tension caused by an active parasite burden.

---

Comprehensive Symptom Support

This medication is generally applied across domains where additional symptomatic support is needed to address conditions presenting with systemic or localized discomfort. It helps address symptom clusters that may become intense or disruptive, such as those related to physical discomfort and digestive strain, supporting general well-being during symptomatic phases. The product is applied in addressing conditions involving these types of common intestinal parasites: nematodes (including roundworms, hookworms, and whipworms) and cestodes (tapeworms).

Clinical Scenarios and Benefits

Cazitel Plus XL is commonly used across conditions characterized by periods of heightened symptoms associated with parasitic infestation. Applied in clinical settings where short-term symptomatic assistance is needed, the product is relevant for easing discomfort. It offers symptomatic relief that helps patients cope more steadily with symptom fluctuations, contributing to easing the overall symptom load during phases when professional symptomatic support is appropriate.

---

Quick Facts

• Focus on Symptoms of Digestive Strain: Covers symptoms related to physical discomfort and irritative states.
• The Benefit: Supports general well-being and assists with maintaining functional stability during episodes of heightened discomfort.

Regulatory References

1. UK Veterinary Medicines Directorate (VMD) Product Information

Who can and cannot use Cazitel Plus XL?

This section defines the official population eligibility and non-eligibility for using Cazitel Plus XL, based strictly on government regulatory documents.

---

Eligibility Scope

Classification	Population Status
Allowed Populations	Primarily indicated for Adult Dogs.
Contraindicated Populations	Animals with a known hypersensitivity to the active ingredients (Praziquantel, Pyrantel embonate, Febantel) or to any excipients.
Age-Related Rule	Use in puppies less than 6 weeks of age is subject to advisories, as certain target infestations are unlikely in this group.

---

Conditional and Restricted Use

Regulatory documents impose specific restrictions on use tied to concurrent medication and pregnancy status.

• Concurrent Medication: The medicine is contraindicated for use simultaneously with piperazine compounds due to potential antagonism.
• Pregnancy Status: Use is not recommended during the first four weeks of pregnancy.
• Conditional Use in Pregnancy: After the first four weeks, use is permitted only following a formal benefit-risk assessment by a veterinarian.

This information establishes that eligibility is strictly governed by the dog's sensitivity profile, reproductive status, and absence of specific concurrent drug therapies.

Interactions with other medicines and products

Cazitel Plus XL contains a fixed combination of three active components, which results in specific regulatory constraints regarding co-administration with other medicinal products. These restrictions are strictly based on officially documented interaction patterns.

Prohibited Combinations and Antagonism Risk The regulatory label explicitly prohibits the simultaneous use of Cazitel Plus XL with piperazine compounds. This restriction is a mandatory constraint classified based on the risk of pharmacodynamic antagonism, where co-administration may reduce the expected anthelmintic effects of the Pyrantel component.

Pharmacodynamic Interactions and Toxicity A risk of toxicity is documented for the concurrent use of this medicine with other cholinergic compounds. This official warning relates to the potential for an additive pharmacodynamic effect.

Pharmacokinetic Modifications (Exposure Alteration) The Praziquantel component is subject to alterations in its systemic exposure (plasma concentration) when administered with certain enzyme-modifying agents. These pharmacokinetic interactions are officially categorized as follows:

Interacting Substance Category	Official Outcome (Praziquantel Exposure)
CYP P-450 enzyme inducers (e.g., Dexamethasone)	Decrease in plasma concentrations
CYP3A4 inhibitors (e.g., Itraconazole)	Increase in plasma concentrations

The official documentation also notes that the administration timing is not strict concerning meals; no starvation is needed before or after treatment, confirming the absence of a required timing-based food interaction.

Cazitel Plus XL utilizes three co-administered pharmacologically active molecules: praziquantel, pyrantel, and febantel.

Praziquantel is rapidly absorbed across the susceptible parasite's tegument, altering membrane permeability. This interaction leads to an instantaneous, massive influx of divalent cations, particularly Ca^2+, resulting in a rapid, spastic, tetanic contraction of the parasite's musculature and subsequent vacuolization and structural disintegration of the syncytial tegument.

Pyrantel acts as a depolarizing neuromuscular agonist, selectively targeting nicotinic acetylcholine receptors in susceptible nematode cells. This agonistic binding induces persistent receptor activation, causing an uninterrupted depolarization of the muscle membrane, which results in spastic paralysis and loss of intestinal attachment.

Febantel, a prodrug, is systemically metabolized into the active benzimidazole derivatives, fenbendazole and oxfendazole. These metabolites function as inhibitors of beta-tubulin polymerization in the susceptible parasites. The inhibition prevents the formation of cellular microtubules, structurally disrupting elements vital for helminth function. This microtubule disruption impairs glucose uptake, initiating a catabolic cascade that depletes endogenous glycogen reserves and significantly reduces intracellular adenosine triphosphate (ATP) concentration, leading to a system-level energy exhaustion.

Cazitel Plus XL is an anthelmintic product strictly intended for oral administration, utilizing a chewable tablet formulation that is the sole approved route of use. The usage protocol is defined by a standardized, single-dose treatment for current mixed parasitic infections, rather than a cyclical or maintenance regimen. The need for and frequency of any repeat treatments are not part of the standard instruction and must be determined by a veterinarian.

---

Dosing Principle and Administration Context

The central principle for using this medicine involves calculating the dose precisely based on the animal’s bodyweight. The regimen is standardized to deliver 5 mg/kg of Praziquantel, 14.4 mg/kg of Pyrantel embonate, and 15 mg/kg of Febantel. This equates to the administration of one XL tablet per 35 kg of bodyweight. For accurate use, the dog’s weight must be determined as exactly as possible.

---

Procedural and Time-Relation Instructions

Administration is simplified by official instructions regarding context. The tablet may be given directly or disguised in food, as the formulation is palatable. Importantly, the official procedure explicitly states that no starvation is necessary either before or after the administration of the dose, thus providing flexibility in timing.

For animals weighing over 35 kg, the protocol requires a combination of one XL tablet supplemented by the necessary number of standard-strength Cazitel Plus tablets to achieve the full target dose. The XL tablet is scored, permitting it to be divided into two equal halves for treating animals weighing approximately 17.5 kg.

Research Evidence / Overview of Studies

This section describes the research evaluating the combination of active substances in Cazitel Plus XL—Praziquantel, Pyrantel Embonate, and Febantel—for use in dogs. The product is authorized for treating mixed infections caused by gastrointestinal roundworms and tapeworms.

---

Research Focus

Initial research explored the compounds' activity, which is designed to address a broad range of intestinal parasites. The combination of Febantel and Pyrantel is investigated for its potential to target key nematode species, including Toxocara canis (ascarids), Ancylostoma caninum (hookworms), and Trichuris vulpis (whipworms). Praziquantel is explored for its activity against cestode species, specifically tapeworms such as Echinococcus and Dipylidium caninum.

---

Clinical Findings

Studies were conducted to evaluate the combination's effectiveness against naturally acquired intestinal parasites in the target species. Key measures assessed were the reduction of faecal egg count (FECR) after administration, which serves as a primary marker for the clearance of various helminths.

Parasite Type	Example Species Studied
Nematodes (Roundworms)	Toxocara canis, Uncinaria stenocephala
Cestodes (Tapeworms)	Echinococcus granulosus, Dipylidium caninum

In various trials, the combination was consistently associated with a notable reduction in egg counts across the studied spectrum of intestinal helminths. Research has also investigated the product's tolerance profile, with studies observing the safety of the combination even when administered at multiples of the recommended dose. Adverse reactions observed in the clinical data are considered very rare (less than 1 in 10,000 animals treated) and typically involve digestive tract disorders.

Key Studies & References

1. SUMMARY OF PRODUCT CHARACTERISTICS: Cazitel Plus XL Tablets for Dogs (Regulatory Document)
2. Publicly Available Assessment Report for a Veterinary Medicinal Product: Cazitel Plus (Regulatory Assessment/Safety)
3. praziquantel/pyrantel pamoate/febantel - Freedom of Information Summary (NADA 141-007) (Regulatory Document)

Common questions about Cazitel Plus XL (FAQ)

---

Q: What are the main ingredients in Cazitel Plus XL?

The official product documentation states that Cazitel Plus XL is a combination product containing three active ingredients: Praziquantel, Pyrantel embonate, and Febantel. The tablets are formulated to deliver standardized amounts of these three components, such as 175 mg of Praziquantel and 525 mg of Febantel, to meet the dosing requirements for larger animals.

Q: How quickly does Cazitel Plus XL usually start to work?

The active components begin to work using different biological processes. Official descriptions of the mechanism of action show that Praziquantel causes rapid contraction and Pyrantel induces spastic paralysis. The effect of the Febantel component, which works by energy depletion, is often described in pharmacological descriptions as manifesting over a two to three day period.

Q: How long does the effect of Cazitel Plus XL last?

The medicine is authorized as a single-dose treatment intended to clear the parasites present at the time of administration. Regulatory sources indicate that one of the active ingredients, Praziquantel, is rapidly metabolized and largely excreted within 24 hours. The product is intended for a current infection, and the frequency of any repeat treatment is a determination made by the prescribing professional.

Q: Is it normal to feel a bit nauseous after using Cazitel Plus XL?

Adverse reactions affecting the digestive system, such as vomiting (emesis) and diarrhoea, are officially classified as very rare. This means that they occur in fewer than 1 out of every 10,000 administrations, according to official regulatory summaries.

Q: Can women who are pregnant or breastfeeding use Cazitel Plus XL?

Official guidance recommends that the medicine not be used during the first four weeks of pregnancy. Use after the first four weeks is conditional upon the professional’s assessment of the benefits and risks. The regulatory documentation does not explicitly address restrictions during the lactation period.

Q: Can Cazitel Plus XL be taken with common over-the-counter pain relievers?

The official product documentation does not list common over-the-counter pain relievers, such as paracetamol, as substances to avoid. The mandatory restrictions focus on prohibiting the simultaneous use of piperazine compounds and other cholinergic compounds due to risks of reduced effect or increased toxicity.

Q: What is the difference between 'side effect' and 'adverse reaction' for Cazitel Plus XL?

In official regulatory language, the term 'adverse reaction' refers to undesirable effects seen after administration that are formally classified based on their frequency. For this medicine, effects like vomiting or lethargy are officially grouped under the classification of very rare adverse reactions, meaning they are observed infrequently.

Q: Can Cazitel Plus XL be split in half if needed?

Yes, regulatory documents indicate the tablet is scored and may be divided into two equal halves. The purpose of this division is to ensure precise dosing for animals that weigh approximately 17.5 kilograms.

Q: Is the research for Cazitel Plus XL long-term or short-term?

The research cited in regulatory documents primarily consists of short-term studies focusing on two main areas: demonstrating effectiveness against the target parasites, and establishing a tolerance profile when the drug is administered as directed or at higher doses.

Q: Is Cazitel Plus XL the same kind of medicine as other products with similar names?

Cazitel Plus XL is defined as a specific fixed triple combination product containing Praziquantel, Pyrantel embonate, and Febantel. This combination is classified as a broad-spectrum anthelmintic, a factor that differentiates it from similar products which may contain only one or two active components.

Q: What are the most commonly reported side effects for this medicine?

According to the official safety profile, adverse reactions such as diarrhoea, vomiting, lethargy, loss of appetite (anorexia), and hyperactivity are all classified as very rare. No adverse effect is classified as 'common' or 'frequent' in the available regulatory summary.

Q: Are there any common foods or supplements that can interfere with Cazitel Plus XL?

Official documentation explicitly notes that no starvation is necessary before or after administration, meaning there is flexibility regarding the timing of meals. The regulatory documents do not provide a specific list of common food types or supplements known to interfere with this medicine.

Q: Does Cazitel Plus XL have any known effects on fertility?

While there is no explicit regulatory statement on fertility, official documents note that studies involving the active substance Febantel have reported teratogenic effects (birth defects) in laboratory animals at high doses. The official product information includes specific restrictions regarding use during the first four weeks of pregnancy.

Q: What does 'contraindicated' mean in relation to Cazitel Plus XL?

In regulatory language, a 'contraindication' indicates that the medicine is not recommended for use under certain specific circumstances, as defined in official documentation. For this product, contraindications include a known hypersensitivity to any of the ingredients, or concurrent use with specific drugs, such as piperazine compounds.

Q: Is there a generic version of Cazitel Plus XL?

Regulatory assessment reports indicate that the active substances used in this product are described as established substances. The product is marketed as a combination of these agents and is one of several similar combination products authorized for use in the same therapeutic class.

Q: What kind of research has been done on Cazitel Plus XL?

The research documented in official reports includes studies focused on confirming the medicine's effectiveness against the target parasites, which is measured by the reduction of parasite egg counts. Additional research has been conducted to investigate the product's tolerance profile, even when administered at doses multiple times higher than the recommendation.

Q: Are the effects of Cazitel Plus XL proven by clinical trials?

The product's regulatory authorization is based on clinical studies demonstrating the activity of the combination against the target parasites, measured by key metrics such as the reduction of faecal egg counts.

Q: What should I do if a side effect gets worse?

Regulatory guidance emphasizes the importance of reporting adverse events. This includes following the recommended procedure for reporting adverse events to the national competent authority or the product’s authorization holder.

Q: Why is Cazitel Plus XL mentioned for a specific age group or weight class?

The 'XL' designation and the dose calculations (e.g., 1 tablet per 35 kg) are specific to the weight class to ensure the correct amount of medicine is given. Advisories are also noted for the very young (e.g., puppies less than 6 weeks old), as certain target infestations are less likely in that specific age group.

Q: Does Cazitel Plus XL have an effect on kidney function?

The regulatory pharmacological summary for one of the active ingredients, Praziquantel, notes that the kidney is the predominant elimination path for the drug and its related compounds from the body.

Q: Can Cazitel Plus XL cause changes in mood or behavior?

The official list of very rare adverse reactions includes general and nervous system effects. These documented effects include lethargy, a lack of appetite (anorexia), and hyperactivity.

Q: Is Cazitel Plus XL considered a new or an established medicine?

While the specific formulation may have been introduced recently, the individual active components—Praziquantel, Pyrantel embonate, and Febantel—are described in official regulatory documents as established active substances within the pharmaceutical field.

Storage and Disposal of Cazitel Plus XL Tablets

The storage and disposal instructions for Cazitel Plus XL are defined by regulatory labeling to ensure product stability and safety. The product does not require any special temperature storage conditions.

Storage Requirements

• The full product, as packaged for sale, has a shelf life of 5 years.
• It must be kept out of the sight and reach of children.
• A half tablet once divided has a limited shelf-life of 14 days and must be returned to the open blister space and inserted back into the outer carton.

Disposal Instructions

Any unused veterinary medicinal product or waste materials must be disposed of in accordance with local requirements. It is strictly required that the medicine should not be disposed of via wastewater.